Thyrocare Technologies Limited Earnings Summary — Q3 FY2026

• Revenue grew 17.8% year-on-year to ₹195.5 crore, though it saw a sequential dip from the high of Q2 FY26.
• The Diagnostic Testing Services segment remains the primary driver, contributing ₹182.4 crore to total revenues.
• Completed a 2:1 bonus share issue on December 1, 2025, which led to a restatement of historical EPS figures.
• Recognized exceptional items of ₹6.16 crore related to the 'New Labour Codes' impact on gratuity and capital restructuring costs.
• Operating margins show significant recovery on a YoY basis despite facing cost pressures from material consumption and employee benefits.
• B2B business model continues to offer high operational efficiency with strong consolidated net profit margins.
• Management noted a non-recurring cost of ₹1.96 crore specifically associated with the capital restructuring during the quarter.

Management remains focused on volume-led growth and maintaining low-cost leadership. Integration with digital pharmacy platforms (PharmEasy/API Holdings) continues to drive synergy and throughput in the diagnostic network. While margins have fluctuated post-pandemic, the strategy is aimed at stabilizing the Operating Profit Margin in the 30% range over the long term.

Improving

The business shows a strong recovery in profitability (48% YoY profit growth) and successful execution of capital actions like the bonus issue, despite seasonal sequential softening.

The company expects long-term healthy double-digit growth in sales and profits. While promoter pledging at the parent level remains a monitorable, operational cash flows and the asset-light franchise model provide a robust buffer for future expansion.